Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

News SummaryMost relevantAll newsSector newsTweets 

Merck & Co., Inc. : Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

share with twitter share with LinkedIn share with facebook
share via e-mail
04/19/2012 | 07:50pm CEST

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx.

In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation.

Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes.

"The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement.

In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations.

Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
06/28 MERCK AND : Colombia takes historic step to peace as rebels lay down guns; NEWS ..
06/28DJMERCK AND : Today's Top Supply Chain and Logistics News From WSJ
06/28 MERCK : New cholesterol drug worked in big study Merck says new type of choleste..
06/28 Factbox - Companies hit by global ransomware attack on June 27
06/28 MERCK AND : hack part of a massive global attack
06/27DJMERCK AND : Says Its Network Was Hit by Global Hack
06/27 MERCK AND : is the target of a massive hack
06/27 Ransomware attack causes disruptions across globe
06/27 MERCK AND : says new type of cholesterol drug worked in big study
06/27 MERCK : Provides Update on REVEAL Outcomes Study of Anacetrapib
More news
Sector news : Pharmaceuticals - NEC
09:22a COVESTRO : vows to cash out to shareholders if no takeover on cards
04:55a MYLAN : Investors call on Mylan chairman, director to step down
06/28 UK blue chips led lower by Hargreaves as strong pound takes toll
06/28DJVECTURA : In Asthma Collaboration With Novartis's Sandoz
06/28DJGLAXOSMITHKLINE : Announces US Filing For Mepolizumab
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/28 Merck's Cautious Statement Suggests Slim Chances Of Anacetrapib Success
06/28 Opportunities In Cyber Security After Growing Number Of Ransomware Attacks
06/28 Comments On REVEAL, Merck's CTEP Inhibitor Study
06/28 WALL STREET BREAKFAST : Fed's Stress Tests - Part 2
06/27 Kala Pharmaceuticals Files For $86 Million IPO
Financials ($)
Sales 2017 39 964 M
EBIT 2017 13 664 M
Net income 2017 7 128 M
Debt 2017 3 171 M
Yield 2017 2,88%
P/E ratio 2017 25,40
P/E ratio 2018 18,98
EV / Sales 2017 4,54x
EV / Sales 2018 4,40x
Capitalization 178 223 M
More Financials
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,4 $
Spread / Average Target 6,4%
Consensus details
EPS Revisions
More Estimates Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY10.68%178 223
JOHNSON & JOHNSON17.19%360 489
ROCHE HOLDING LTD.8.34%226 454
NOVARTIS11.74%223 476
PFIZER3.91%200 985
SANOFI12.74%124 566
More Results